Want to see NGNE full AI Analyst Report?
NGNE Stock Chart & Stats
$27.85
-$0.86(-3.93%)
At close: 4:00 PM EST
$27.85
-$0.86(-3.93%)
Day’s Range― - ―
52-Week Range$15.93 - $37.27
Previous CloseN/A
Volume20.02K
Average Volume (3M)225.72K
Market Cap
$558.44M
Enterprise Value$371.51M
Total Cash (Recent Filing)$243.18M
Total Debt (Recent Filing)$9.13M
Price to Earnings (P/E)―
Beta3.01
Next Earnings
Aug 07, 2026EPS Estimate
-1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.03
Shares Outstanding15,801,901
10 Day Avg. Volume272,921
30 Day Avg. Volume225,725
Financial Highlights & Ratios
PEG Ratio5.20
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.71
Enterprise Value/Ebitda-3.89
Forecast
1Y Price Target
$80.00Price Target Upside187.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayA material equity offering that provides ~ $134.8M in net proceeds extends funding visibility into Q1 2029, materially lowering near-term financing risk. This durable funding runway supports completion of registrational studies and regulatory filings, enabling strategic development decisions.
Durable Clinical Benefit For NGN-401Long-term Phase 1/2 data showing sustained, multidomain functional gains and 47 developmental milestones across patients through 30 months supports a credible efficacy signal and tolerability at the registrational dose. Durable benefits increase the probability of regulatory success and long-term commercial value.
Commercial And Governance StrengtheningHiring an experienced rare neurology CCO and expanding board governance indicates the company is building commercialization capabilities and aligning oversight with launch objectives. Strong leadership depth is a durable advantage for launch planning and payer/provider engagement execution.
Bears Say
High Cash BurnPersistently large negative operating and free cash flows (TTM operating cash flow -$81.9M; free cash flow -$82.6M) signal an ongoing structural cash drain. Continued high burn increases dependency on external financing and compresses flexibility for parallel programs or unexpected delays.
Widening Net Losses / Pre-commercial ProfileAs a pre-revenue biotech, losses have materially widened (2025 net loss -$90.4M; TTM -$98.6M) without internal revenue to offset spending. This structural unprofitability limits self-funding, lowers resilience to setbacks, and keeps long-term returns dependent on successful approvals and commercialization.
Reliance On Equity FinancingThe company fundamentally depends on capital raises and partner deals to fund operations. This structural financing model exposes shareholders to recurrent dilution risk and market-timing execution risk, and ties program continuity to access to favorable external financing conditions.
Neurogene News
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $15.93 and its highest was $37.27 in the past 12 months.
What is Neurogene’s market cap?
Neurogene’s market cap is $558.44M.
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Aug 07, 2026 which is in 35 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on May 12, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.296 by -$0.094.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -1.42.
How many shares outstanding does Neurogene have?
Neurogene has 15,801,901 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.296. Following the earnings report the stock price went up 3.424%.
Which hedge fund is a major shareholder of Neurogene?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.00 (187.25% Upside)
$80.00 (187.25% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.3%
Last 30 Days ▲ 14.6%
Last 30 Days ▲ 14.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.14%
12-Months-Change
Fundamentals
Return on Equity
-37.88%
Trailing 12-Months
Asset Growth
-16.54%
Trailing 12-Months
Company Description
Neurogene
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$80.00
▲(187.25% Upside)
Technical Analysis
Silence Therapeutics
―
Atea Pharmaceuticals
―
Elicio Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
9.34% Insiders
8.34% Mutual Funds
69.14% Other Institutional Investors
3.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---